Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid

Aims The purpose of this study is to investigate the regulation of adipose tissue insulin resistance with DPP-4 inhibitors in treatment-naive subjects with T2DM and to examine its relation to other diabetic parameters. Subjects and methods A total of 147 subjects were treated with alogliptin 12.5–25 mg/day ( n = 55), sitagliptin 25–50 mg/day ( n = 49), or teneligliptin 10–20 mg/day ( n = 43) monotherapy for 3 months. Changes in adipo-IR, a mathematical model used to evaluate adipose tissue insulin resistance, and various diabetic parameters were analyzed in this prospective, non-randomized observational study. Results Among these three drugs, only alogliptin significantly reduced adipo-IR (−25.9%, p